BIO-TECHNE Corp (TECH) income statement

TECHNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends June 30

Financials through Q1 FY2027, quarter ended Sep 30, 2026Last filing: 10-Q/A on Nov 12, 2026Score 11/3040% above fair value

$72.80−0.04 (-0.05%)

Close on Nov 13, 2026Market cap $11.43BP/E 66.8Yield 0.44%

BIO-TECHNE Corp income statement

Annual Quarterly TTM

Periods

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2026 CY2026 2026-06-30	FY 2025 CY2025 2025-06-30	FY 2024 CY2024 2024-06-30	FY 2023 CY2023 2023-06-30	FY 2022 CY2022 2022-06-30	FY 2021 CY2021 2021-06-30	FY 2020 CY2020 2020-06-30	FY 2019 CY2019 2019-06-30	FY 2018 CY2018 2018-06-30	FY 2017 CY2017 2017-06-30	FY 2016 CY2016 2016-06-30	FY 2015 CY2015 2015-06-30	FY 2014 CY2014 2014-06-30	FY 2013 CY2013 2013-06-30	FY 2012 CY2012 2012-06-30	FY 2011 CY2011 2011-06-30	FY 2010 CY2010 2010-06-30	FY 2009 CY2009 2009-06-30
Revenue	1,215	1,220	1,159	1,137	1,106	931	739	714	643	563	499	452	358	311	315	290	269	264
Cost of Revenue	416	429	389	367	349	298	255	241	211	188	162	145	106	79	79	65	55	56
Gross Profit	799	790	770	770	756	633	483	473	432	375	337	307	251	231	236	225	214	208
Research & Development	95	99	97	92	87	71	65	62	55	54	45	41	31	29	28	26	25	24
Selling, General & Admin	452	589	466	378	373	325	261	264	241	200	141	119	61	43	42	36	33	34
Advertising Expenses	3.00	3.20	4.10	4.80	4.60	4.70	4.20	4.10	3.80	4.50	5.20	4.10	3.40	3.20	3.40	2.90	3.00	3.00
Operating Expenses	547	688	563	471	460	396	326	327	296	254	186	160	92	73	70	62	58	57
Operating Income	252	102	207	299	297	237	157	147	136	121	151	147	160	0.16	166	163	156	151
Interest Expense	9.63	8.51	16	11	11	14	19	22	10	7.36	1.75	1.54	0	0	–	–	–	–
Interest & Investment Income	4.22	3.89	3.32	3.41	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Income from Equity Investments	0.89	0.94	-6.84	-1.14	–	–	–	–	–	–	–	0	0	0.57	-0.60	-0.93	-1.51	-1.29
Other Non-Operating Income	-11	-3.79	-21	40	4.80	-89	119	-35	-10	-8.62	-3.11	7.14	1.64	2.19	-4.01	1.93	0.12	4.58
Merger & Restructuring Charges	–	–	12	3.83	1.64	0.14	0.09	–	0.38	–	–	–	–	–	–	–	–	–
Asset Impairment Charges	–	0	0	0	19	0	0	0	0	0	0	0	0	–	–	–	–	–
Gain (Loss) on Investments	-5.86	–	0.28	49	15	-68	–	–	–	–	–	–	–	–	–	–	–	–
Legal Settlements	–	–	-3.51	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Pretax Income	241	98	186	339	301	148	276	112	126	112	147	154	161	161	162	165	156	–
Income Tax Expense	59	25	18	53	38	8.59	47	16	-0.20	36	43	46	50	48	50	53	47	50
Net Income incl. Noncontrolling Interests	182	73	168	285	263	140	229	96	–	–	–	–	–	–	–	–	–	–
Minority Interest in Earnings	–	–	–	0.18	-8.95	-0.83	0	0	–	–	–	–	–	–	–	–	–	–
Net Income	–	73	168	285	272	140	229	96	126	76	104	108	111	113	112	112	110	105
Net Income to Common	182	73	168	285	272	140	229	96	126	76	104	–	–	–	–	–	–	–
EPS (Basic)(per share)	1.17	0.47	1.07	1.81	1.73	0.91	1.50	0.64	0.84	0.51	0.70	0.73	0.75	0.77	0.76	0.76	0.74	0.70
EPS (Diluted)(per share)	1.16	0.46	1.05	1.76	1.66	0.87	1.46	0.62	0.83	0.51	0.70	0.72	0.75	0.76	0.76	0.76	0.74	0.70
Shares Outstanding (Basic, Weighted)(shares)	156	158	158	157	157	155	153	151	150	149	149	148	148	147	148	148	149	151
Shares Outstanding (Diluted, Weighted)(shares)	157	160	161	162	164	162	158	156	152	150	149	149	148	148	148	149	149	152
Dividend per Share(per share)	0.32	0.32	0.32	0.32	0.32	0.32	0.32	0.32	0.32	0.32	0.32	0.32	0.31	0.30	0.28	0.27	0.26	0.19
EBITDA	349	212	318	406	398	325	240	225	201	181	193	184	179	12	179	172	164	159

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Sep 30, 2026

Profitability, TTM

Gross margin: 65.8%
Operating margin: 19.6%
Net margin: –
Return on equity, FY2026: –

Financial strength

Current ratio: 2.28
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 96.9%

Valuation

P/E ratio: 66.8
Price to sales: 9.31
Price to book: 5.28
Dividend yield: 0.44%

See a number that looks wrong?